main navigation
MSGPP - Home
Project Description
  Flow Diagrams
Contact Information
  Program Project Members
Target Diseases & Organisms
* Malaria
   Plasmodium falciparum
   Plasmodium vivax
* Chagas' Disease
    [American Trypanosomiasis]
   Trypanosoma cruzi
* Sleeping Sickness
    [African Trypanosomiasis]
   Trypanosoma brucei
* Leishmaniasis
   Leishmania spp.
* Amoebiasis
   Entamoeba histolytica
* Giardiasis
   Giardia lamblia
* Toxoplasmosis
   Toxoplasma gondii
* Cryptosporidiosis
   Cryptosporidium parvum
Genome Databases
Target Progress
Ligand Screening
Papers by MSGPP
Related Links/Resources
Employment Opportunities
MSGPP

AFRICAN TRYPANOSOMIASIS
African Sleeping Sickness (Trypanosoma brucei)

African Trypanosomiasis (African Sleeping Sickness) has the potential to infect around sixty million people in thirty-six sub-Saharan African countries. Major epidemics have been reported in Angola, Democratic Republic of Congo and Sudan. The unicellular parasite is transmitted by the tse-tse fly. Current World Health Organization (WHO) estimates show that 300,000 to 500,000 people are infected and most will die within two years. These trypanosomids display antigenic variation and thus they easily develop resistance to drugs. In any case, the current drug treatments are toxic to humans. Further understanding of these parasites and drug development is needed to remedy this disease.

Organism Trypanosoma brucei
At Risk 60 million - sub-Saharan Africa
Humans Infected 300-500 thousand
Disease Outcome Uniformly fatal within two years
Vaccine Prospects Poor due to antigenic variation
Available Drugs Toxic, difficult to deliver
Drug Resistance Documented

General Information: Medline, World Health Organization